Introduction

On April 1, 2026, the third round of tariff reductions under the Regional Comprehensive Economic Partnership (RCEP) took effect, bringing significant changes for China's medical supplies exporters. Vietnam eliminated tariffs on Chinese-made non-woven medical dressings (HS 3005.90), while Malaysia removed import quotas for medical protective masks (HS 6307.90). These adjustments particularly benefit manufacturers and traders in the medical consumables sector, with industry analysts projecting a 25%+ quarterly export growth to Vietnam and Malaysia.

Event Overview

The confirmed policy changes effective April 1, 2026 include:

• Vietnam reduced tariffs from 5.5% to 0% for Chinese medical non-woven dressings (HS 3005.90)
• Malaysia abolished annual import quotas for Chinese medical protective masks (HS 6307.90), applying a 3.2% RCEP agreed rate instead

Impact on Sub-sectors

Medical Non-woven Manufacturers

Direct exporters of wound care products gain immediate price competitiveness in Vietnam. Analysis suggests Vietnamese hospitals may shift 15-20% procurement volume from local suppliers to Chinese exporters within 12 months.

PPE Producers

Mask manufacturers previously constrained by Malaysia's quota system can now expand market share. The 3.2% tariff represents a 40% reduction from most-favored-nation rates, potentially lowering retail prices by 8-12% in Malaysian pharmacies.

Medical Trade Companies

Distributors should note Vietnam's new certification requirements for medical dressings (Circular 30/2024/TT-BYT) taking effect June 2026, which may affect shipment clearance timelines.

Key Considerations for Businesses

Monitor Implementation Details

Verify Vietnam's customs system has updated HS 3005.90 tariff codes, as transitional periods sometimes cause classification discrepancies.

Adjust Pricing Strategy

For Malaysia-bound masks, maintain 5-7% price buffer despite quota removal, as logistics bottlenecks at Port Klang frequently cause unexpected costs.

Documentation Preparation

Ensure all medical exports carry:

• RCEP Certificates of Origin (Form R)
• Updated Free Sale Certificates
• Vietnamese/Malay translations of product specifications

Industry Perspective

From an industry standpoint, these changes signal ASEAN's strategic shift toward diversified medical supply chains rather than temporary pandemic measures. The removal of non-tariff barriers (Malaysia's quotas) carries more significance than tariff reductions alone. Medical exporters should view this as part of a three-year RCEP implementation roadmap, with further ASEAN medical device harmonization expected by 2027.

Conclusion

These RCEP adjustments create tangible opportunities for Chinese medical suppliers in two key ASEAN markets. However, the real impact will depend on how quickly regional distributors adjust procurement patterns and whether competing suppliers from Japan/Korea leverage their own RCEP advantages. Businesses should prioritize compliance readiness while cautiously expanding production capacity.

Sources

• RCEP Secretariat: Third Round Tariff Commitments (2026)
• Vietnam Ministry of Finance Notice 45/2026/TT-BTC
• Malaysia Royal Customs Circular RCEP/IMP/2026-04
• Note: Vietnam's medical device certification changes (effective June 2026) require separate monitoring